<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22877087</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2012</Year><Month>Aug</Month><Day>09</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Immunization with recombinant enterovirus 71 viral capsid protein 1 fragment stimulated antibody responses in hamsters.</ArticleTitle><Pagination><StartPage>155</StartPage><MedlinePgn>155</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1743-422X-9-155</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) causes severe neurological diseases resulting in high mortality in young children worldwide. Development of an effective vaccine against EV71 infection is hampered by the lack of appropriate animal models for efficacy testing of candidate vaccines. Previously, we have successfully tested the immunogenicity and protectiveness of a candidate EV71 vaccine, containing recombinant Newcastle disease virus capsids that display an EV71 VP1 fragment (NPt-VP11-100) protein, in a mouse model of EV71 infection. A drawback of this system is its limited window of EV71 susceptibility period, 2&#x2009;weeks after birth, leading to restricted options in the evaluation of optimal dosing regimens. To address this issue, we have assessed the NPt-VP11-100 candidate vaccine in a hamster system, which offers a 4-week susceptibility period to EV71 infection. Results obtained showed that the NPt-VP11-100 candidate vaccine stimulated excellent humoral immune response in the hamsters. Despite the high level of antibody production, they failed to neutralize EV71 viruses or protect vaccinated hamsters in viral challenge studies. Nevertheless, these findings have contributed towards a better understanding of the NPt-VP11-100 recombinant protein as a candidate vaccine in an alternative animal model system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ch'ng</LastName><ForeName>Wei-Choong</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, 43400, UPM, Serdang, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanbridge</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Kum-Thong</ForeName><Initials>KT</Initials></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Kien-Chai</ForeName><Initials>KC</Initials></Author><Author ValidYN="Y"><LastName>Yusoff</LastName><ForeName>Khatijah</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Shafee</LastName><ForeName>Norazizah</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008647" MajorTopicYN="N">Mesocricetus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22877087</ArticleId><ArticleId IdType="pmc">PMC3462122</ArticleId><ArticleId IdType="doi">10.1186/1743-422X-9-155</ArticleId><ArticleId IdType="pii">1743-422X-9-155</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20:895&#x2013;904. doi: 10.1016/S0264-410X(01)00385-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu CH, Chu C, He CC, Lin TY. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect. 2006;8:1671&#x2013;1678. doi: 10.1016/j.micinf.2006.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2006.01.021</ArticleId><ArticleId IdType="pubmed">16815726</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivasamugham LA, Cardosa MJ, Tan WS, Yusoff K. Recombinant Newcastle Disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits. J Med Virol. 2006;78:1096&#x2013;1104. doi: 10.1002/jmv.20668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20668</ArticleId><ArticleId IdType="pubmed">16789020</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CS, Cardosa MJ. High-titred neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1. Arch Virol. 2007;152:1069&#x2013;1073. doi: 10.1007/s00705-007-0941-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-007-0941-1</ArticleId><ArticleId IdType="pubmed">17318736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Badmanathan M, Devi S, Leong KL, Cardosa MJ, Wong KT. Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. J Neuropathol Exp Neurol. 2008;67:532&#x2013;542. doi: 10.1097/NEN.0b013e31817713e7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31817713e7</ArticleId><ArticleId IdType="pubmed">18520772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch'ng WC, Saw WT, Yusoff K, Shafee N. Immunogenicity of a truncated enterovirus 71 VP1 protein fused to a Newcastle disease virus nucleocapsid protein fragment in mice. Acta Virol. 2011;55:227&#x2013;233. doi: 10.4149/av_2011_03_227.</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/av_2011_03_227</ArticleId><ArticleId IdType="pubmed">21978156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch'ng WC, Stanbridge EJ, Ong KC, Wong KT, Yusoff K, Shafee N. Partial protection against enterovirus 71 (EV71) infection in a mouse model immunized with recombinant newcastle disease virus capsids displaying the EV71 VP1 fragment. J Med Virol. 2011;83:1783&#x2013;1791. doi: 10.1002/jmv.22198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.22198</ArticleId><ArticleId IdType="pubmed">21837796</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegrist CA. The challenges of vaccine responses in early life: selected examples. J Comp Pathol. 2007;137(Suppl 1):S4&#x2013;S9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17559867</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, Vasilenko S, Brodvarova I, Nikolova M, Gyurova S. et al.Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol. 1979;60:329&#x2013;340. doi: 10.1007/BF01317504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01317504</ArticleId><ArticleId IdType="pubmed">228639</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua BH, Phuektes P, Sanders SA, Nicholls PK, McMinn PC. The molecular basis of mouse adaptation by human enterovirus 71. J Gen Virol. 2008;89:1622&#x2013;1632. doi: 10.1099/vir.0.83676-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.83676-0</ArticleId><ArticleId IdType="pubmed">18559932</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava B, Blazejewska P, Hessmann M, Bruder D, Geffers R, Mauel S, Gruber AD, Schughart K. Host genetic background strongly influences the response to influenza a virus infections. PLoS One. 2009;4:e4857. doi: 10.1371/journal.pone.0004857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0004857</ArticleId><ArticleId IdType="pmc">PMC2654507</ArticleId><ArticleId IdType="pubmed">19293935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, Brown EG, Holtzman MJ, Brody SL. Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J Virol. 2006;80:7469&#x2013;7480. doi: 10.1128/JVI.02677-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02677-05</ArticleId><ArticleId IdType="pmc">PMC1563738</ArticleId><ArticleId IdType="pubmed">16840327</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>